| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| A Parabiaghi, M Tettamanti, B D'Avanzo, A Barbat. Metabolic syndrome and drug discontinuation in schizophrenia: a randomized trial comparing aripiprazole olanzapine and haloperidol. Acta psychiatrica Scandinavica. vol 133. issue 1. 2016-11-14. PMID:26252780. |
metabolic syndrome and drug discontinuation in schizophrenia: a randomized trial comparing aripiprazole olanzapine and haloperidol. |
2016-11-14 |
2023-08-13 |
Not clear |
| Adam J Savitz, Rosanne Lane, Isaac Nuamah, Srihari Gopal, David Houg. Efficacy and safety of paliperidone extended release in adolescents with schizophrenia: a randomized, double-blind study. Journal of the American Academy of Child and Adolescent Psychiatry. vol 54. issue 2. 2016-10-28. PMID:25617253. |
to evaluate the efficacy, safety, and tolerability of paliperidone extended release (er) relative to aripiprazole in adolescent schizophrenia. |
2016-10-28 |
2023-08-13 |
Not clear |
| Leslie Citrome, Yangchun Du, Robert Risinger, Srdjan Stankovic, Amy Claxton, Jacqueline Zummo, Anjana Bose, Bernard L Silverman, Elliot W Ehric. Effect of aripiprazole lauroxil on agitation and hostility in patients with schizophrenia. International clinical psychopharmacology. vol 31. issue 2. 2016-10-25. PMID:26517202. |
effect of aripiprazole lauroxil on agitation and hostility in patients with schizophrenia. |
2016-10-25 |
2023-08-13 |
Not clear |
| Leslie Citrome, Yangchun Du, Robert Risinger, Srdjan Stankovic, Amy Claxton, Jacqueline Zummo, Anjana Bose, Bernard L Silverman, Elliot W Ehric. Effect of aripiprazole lauroxil on agitation and hostility in patients with schizophrenia. International clinical psychopharmacology. vol 31. issue 2. 2016-10-25. PMID:26517202. |
this study aimed to evaluate the effects of aripiprazole lauroxil on hostility and aggressive behavior in patients with schizophrenia. |
2016-10-25 |
2023-08-13 |
Not clear |
| Leslie Citrome, Yangchun Du, Robert Risinger, Srdjan Stankovic, Amy Claxton, Jacqueline Zummo, Anjana Bose, Bernard L Silverman, Elliot W Ehric. Effect of aripiprazole lauroxil on agitation and hostility in patients with schizophrenia. International clinical psychopharmacology. vol 31. issue 2. 2016-10-25. PMID:26517202. |
patients aged 18-70 years with a diagnosis of schizophrenia and currently experiencing an acute exacerbation or relapse were randomized to intramuscular (im) aripiprazole lauroxil 441 mg (n=207), 882 mg (n=208), or placebo (n=207) for 12 weeks. |
2016-10-25 |
2023-08-13 |
Not clear |
| Leslie Citrome, Yangchun Du, Robert Risinger, Srdjan Stankovic, Amy Claxton, Jacqueline Zummo, Anjana Bose, Bernard L Silverman, Elliot W Ehric. Effect of aripiprazole lauroxil on agitation and hostility in patients with schizophrenia. International clinical psychopharmacology. vol 31. issue 2. 2016-10-25. PMID:26517202. |
treatment with aripiprazole lauroxil resulted in decreases in agitation and hostility in patients with schizophrenia and this antihostility effect appears to be independent of a general antipsychotic effect. |
2016-10-25 |
2023-08-13 |
Not clear |
| Hidenobu Suzuki, Gou Sekiguch. Influence of aripiprazole once monthly on clinical symptoms and cognitive function in two schizophrenia patients: Preliminary results. Psychiatry and clinical neurosciences. vol 70. issue 1. 2016-10-24. PMID:26556467. |
influence of aripiprazole once monthly on clinical symptoms and cognitive function in two schizophrenia patients: preliminary results. |
2016-10-24 |
2023-08-13 |
Not clear |
| Ying Qiao, Fuzhong Yang, Chunbo Li, Qian Guo, Hui Wen, Suoyu Zhu, Qiong Ouyang, Weidi Shen, Jianhua Shen. Add-on effects of a low-dose aripiprazole in resolving hyperprolactinemia induced by risperidone or paliperidone. Psychiatry research. vol 237. 2016-10-12. PMID:26921057. |
this study investigated the effects of a low-dose aripiprazole adjunctive treatment for risperidone- or paliperidone-induced hyperprolactinemia in han chinese women with schizophrenia. |
2016-10-12 |
2023-08-13 |
Not clear |
| Leslie Citrom. Aripiprazole long-acting injectable formulations for schizophrenia: aripiprazole monohydrate and aripiprazole lauroxil. Expert review of clinical pharmacology. vol 9. issue 2. 2016-10-07. PMID:26573020. |
aripiprazole long-acting injectable formulations for schizophrenia: aripiprazole monohydrate and aripiprazole lauroxil. |
2016-10-07 |
2023-08-13 |
Not clear |
| Yoshikazu Takaesu, Taishiro Kishimoto, Akiko Murakoshi, Nobutada Takahashi, Yuichi Inou. Factors associated with discontinuation of aripiprazole treatment after switching from other antipsychotics in patients with chronic schizophrenia: A prospective observational study. Psychiatry research. vol 236. 2016-09-28. PMID:26743338. |
factors associated with discontinuation of aripiprazole treatment after switching from other antipsychotics in patients with chronic schizophrenia: a prospective observational study. |
2016-09-28 |
2023-08-13 |
human |
| Yoshikazu Takaesu, Taishiro Kishimoto, Akiko Murakoshi, Nobutada Takahashi, Yuichi Inou. Factors associated with discontinuation of aripiprazole treatment after switching from other antipsychotics in patients with chronic schizophrenia: A prospective observational study. Psychiatry research. vol 236. 2016-09-28. PMID:26743338. |
the purpose of the study was to identify factors associated with discontinuation of aripiprazole after switching from other antipsychotics in patients with schizophrenia in real world clinical settings. |
2016-09-28 |
2023-08-13 |
human |
| Lisa A Raedle. Aripiprazole Lauroxil (Aristada): Long-Acting Atypical Antipsychotic Injection Approved for the Treatment of Patients with Schizophrenia. American health & drug benefits. vol 9. issue Spec Feature. 2016-09-26. PMID:27668044. |
aripiprazole lauroxil (aristada): long-acting atypical antipsychotic injection approved for the treatment of patients with schizophrenia. |
2016-09-26 |
2023-08-13 |
Not clear |
| Martin P Cru. Aripiprazole Lauroxil (Aristada): An Extended-Release, Long-Acting Injection For the Treatment of Schizophrenia. P & T : a peer-reviewed journal for formulary management. vol 41. issue 9. 2016-09-16. PMID:27630522. |
aripiprazole lauroxil (aristada): an extended-release, long-acting injection for the treatment of schizophrenia. |
2016-09-16 |
2023-08-13 |
Not clear |
| Martin P Cru. Aripiprazole Lauroxil (Aristada): An Extended-Release, Long-Acting Injection For the Treatment of Schizophrenia. P & T : a peer-reviewed journal for formulary management. vol 41. issue 9. 2016-09-16. PMID:27630522. |
aripiprazole lauroxil (aristada) for the treatment of schizophrenia. |
2016-09-16 |
2023-08-13 |
Not clear |
| Jun Ishigooka, Takamasa Noda, Kosuke Nishiyama, Noriko Tamaru, Tomoko Shima, Yumiko Yamasaki, Yoshihiro Tador. [Pharmacokinetics and safety of aripiprazole long-acting injection, following multiple deltoid administrations in schizophrenia patients in Japan]. Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology. vol 36. issue 3. 2016-09-12. PMID:27506082. |
[pharmacokinetics and safety of aripiprazole long-acting injection, following multiple deltoid administrations in schizophrenia patients in japan]. |
2016-09-12 |
2023-08-13 |
Not clear |
| Jun Ishigooka, Takamasa Noda, Kosuke Nishiyama, Noriko Tamaru, Tomoko Shima, Yumiko Yamasaki, Yoshihiro Tador. [Pharmacokinetics and safety of aripiprazole long-acting injection, following multiple deltoid administrations in schizophrenia patients in Japan]. Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology. vol 36. issue 3. 2016-09-12. PMID:27506082. |
aripiprazole once-monthly (aom) was previously approved for treatment of schizophrenia as monthly injections in the gluteal muscle. |
2016-09-12 |
2023-08-13 |
Not clear |
| Jarosław Sobiś, Monika Rykaczewska-Czerwińska, Elżbieta Świętochowska, Piotr Gorczyc. Therapeutic effect of aripiprazole in chronic schizophrenia is accompanied by anti-inflammatory activity. Pharmacological reports : PR. vol 67. issue 2. 2016-09-06. PMID:25712663. |
therapeutic effect of aripiprazole in chronic schizophrenia is accompanied by anti-inflammatory activity. |
2016-09-06 |
2023-08-13 |
Not clear |
| Tzung-Jeng Hwang, Wei-Ming Lo, Hung-Yu Chan, Ching-Feng Lin, Ming H Hsieh, Chen-Chun Liu, Chih-Min Liu, Hai-Gwo Hwu, Ching-Hua Kuo, Wei J Che. Fast Versus Slow Strategy of Switching Patients With Schizophrenia to Aripiprazole From Other Antipsychotics. Journal of clinical psychopharmacology. vol 35. issue 6. 2016-08-30. PMID:26488675. |
fast versus slow strategy of switching patients with schizophrenia to aripiprazole from other antipsychotics. |
2016-08-30 |
2023-08-13 |
Not clear |
| Serena Deiana, Akihito Watanabe, Yuki Yamasaki, Naoki Amada, Tetsuro Kikuchi, Colin Stott, Gernot Riede. MK-801-induced deficits in social recognition in rats: reversal by aripiprazole, but not olanzapine, risperidone, or cannabidiol. Behavioural pharmacology. vol 26. issue 8 Spec No. 2016-08-22. PMID:26287433. |
collectively, the combined activity of aripiprazole on dopamine d2 and serotonin 5ht1a receptors appears to provide a significant advantage over risperidone and olanzapine with respect to the rescue of cognitive deficits reminiscent of schizophrenia. |
2016-08-22 |
2023-08-13 |
human |
| Hamid Reza Fard Masoumi, Mahiran Basri, Wan Sarah Samiun, Zahra Izadiyan, Chaw Jiang Li. Enhancement of encapsulation efficiency of nanoemulsion-containing aripiprazole for the treatment of schizophrenia using mixture experimental design. International journal of nanomedicine. vol 10. 2016-08-18. PMID:26508853. |
enhancement of encapsulation efficiency of nanoemulsion-containing aripiprazole for the treatment of schizophrenia using mixture experimental design. |
2016-08-18 |
2023-08-13 |
Not clear |